Immunosuppressive treatments in multiple sclerosis

Handbook of Clinical Neurology

Volumn 122, Issue , 2014, Pages 503-511

  Okuda, Darin T ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Aggressive disease; Azathioprine; Complications of therapy; Cyclophosphamide; Methotrexate; Mitoxantrone; Mycophenolate mofetil; Progressive disease

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

AGGRESSIVE DISEASE; ARTICLE; COMPLICATIONS OF THERAPY; DRUG APPROVAL; HUMAN; IMMUNOLOGY; MULTIPLE SCLEROSIS; PROGRESSIVE DISEASE; TREATMENT OUTCOME;

AGGRESSIVE DISEASE; AZATHIOPRINE; COMPLICATIONS OF THERAPY; CYCLOPHOSPHAMIDE; METHOTREXATE; MITOXANTRONE; MYCOPHENOLATE MOFETIL; PROGRESSIVE DISEASE;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 84893483687     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52001-2.00022-4     Document Type: Chapter

References (43)

1. Ahrens N., Salama A., Haas J. Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J Neurol 2001, 248:713-714.
2. Aimard G., Girard P.F., Raveau J. Multiple sclerosis and the autoimmunization process. Treatment by antimitotics. Lyon Med 1966, 215:345-352.
3. Amato M.P., Pracucci G., Ponziani G., et al. Long-term safety of azathioprine therapy in multiple sclerosis. Neurology 1993, 43:831-833.
4. Balashov K.E., Smith D.R., Khoury S.J., et al. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A 1997, 94:599-603.
5. British and Dutch Multiple Sclerosis Azathioprine Trial Group Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988, 2:179-183.
6. Casetta I., Iuliano G., Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev 2007, CD003982.
7. Chabas D., Ness J., Belman A., et al. Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology 2010, 74:399-405.
8. Cohen J.A., Imrey P.B., Calabresi P.A., et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 2009, 72:535-541.
9. Currier R.D., Haerer A.F., Meydrech E.F. Low dose oral methotrexate treatment of multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry 1993, 56:1217-1218.
10. Etemadifar M., Janghorbani M., Shaygannejad V. Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. J Neurol 2007, 254:1723-1728.
11. Fidler J.M., Dejoy S.Q., Smith F.R., et al. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol 1986, 136:2747-2754.
12. Franciotta D., Salvetti M., Lolli F., et al. B cells and multiple sclerosis. Lancet Neurol 2008, 7:852-858.
13. Frohman E.M., Cutter G., Remington G., et al. A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord 2010, 3:15-28.
14. Gonsette R.E., Demonty L., Delmotte P. Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years. J Neurol 1977, 214:173-181.
15. Goodin D.S., Frohman E.M., Garmany G.P., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002, 58:169-178.
16. Goodkin D.E., Rudick R.A., Vanderbrug Medendorp S., et al. Low-dose (7.5mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995, 37:30-40.
17. Goodkin D.E., Rudick R.A., Vanderbrug Medendorp S., et al. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs. Neurology 1996, 47:1153-1157.
18. Gorman M.P., Healy B.C., Polgar-Turcsanyi M., et al. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009, 66:54-59.
19. Gray O.M., McDonnell G.V., Forbes R.B. A systematic review of oral methotrexate for multiple sclerosis. Mult Scler 2006, 12:507-510.
20. Hartung H.P., Gonsette R., Konig N., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002, 360:2018-2025.
21. Havrdova E., Zivadinov R., Krasensky J., et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler 2009, 15:965-976.
22. Hommes O.R., Prick J.J., Lamers K.J. Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin Neurol Neurosurg 1975, 78:59-72.
23. Karni A., Balashov K., Hancock W.W., et al. Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis. J Neuroimmunol 2004, 146:189-198.
24. Kopadze T., Dehmel T., Hartung H.P., et al. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Arch Neurol 2006, 63:1572-1578.
25. Le Page E., Leray E., Taurin G., et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008, 79:52-56.
26. Makhani N., Gorman M.P., Branson H.M., et al. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 2009, 72:2076-2082.
27. Marriott J.J., Miyasaki J.M., Gronseth G., et al. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010, 74:1463-1470.
28. Massacesi L., Parigi A., Barilaro A., et al. Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch Neurol 2005, 62:1843-1847.
29. Miljkovic D., Samardzic T., Drakulic D., et al. Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms. Cytokine 2002, 19:181-186.
30. Neuhaus O., Wiendl H., Kieseier B.C., et al. Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005, 168:128-137.
31. Oger J. Immunosuppression: promises and failures. J Neurol Sci 2007, 259:74-78.
32. Radis C.D., Kahl L.E., Baker G.L., et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995, 38:1120-1127.
33. Remington G.M., Treadaway K., Frohman T., et al. A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS). Ther Adv Neurol Disord 2010, 3:3-13.
34. Sadiq S.A., Simon E.V., Puccio L.M. Intrathecal methotrexate treatment in multiple sclerosis. J Neurol 2010, 257:1806-1811.
35. Serafini B., Rosicarelli B., Magliozzi R., et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004, 14:164-174.
36. Smith I.E. Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 1983, 10:103-115.
37. Smith D.R., Balashov K.E., Hafler D.A., et al. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol 1997, 42:313-318.
38. Talar-Williams C., Hijazi Y.M., Walther M.M., et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996, 124:477-484.
39. Tiede I., Fritz G., Strand S., et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003, 111:1133-1145.
40. Vermersch P., Waucquier N., Michelin E., et al. Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis. Eur J Neurol 2007, 14:85-89.
41. Vollmer T., Panitch H., Bar-Or A., et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008, 14:663-670.
42. Waubant E., Chabas D., Okuda D.T., et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol 2009, 66:967-971.
43. Weiner H.L. Immunosuppressive treatment in multiple sclerosis. J Neurol Sci 2004, 223:1-11.